2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161999
    α-Glucosidase-IN-73 98%
    α-Glucosidase-IN-73 (compound 16b) is an α-Glucosidase inhibitor with IC50 of 0.158 μM. α-Glucosidase-IN-73 can activate PPAR γ. α-Glucosidase-IN-73 can be used in anti-diabetic and anti-inflammatory studies.
    α-Glucosidase-IN-73
  • HY-162004
    NF-κB-IN-14 3019972-01-8 98%
    NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model.
    NF-κB-IN-14
  • HY-162013
    NLRP3-IN-26 2927413-30-5 98%
    NLRP3-IN-26 (compound 15Z) is a NLRP3 inhibitor with the IC50 of 0.13 μM. NLRP3-IN-26 can be used for DSS-induced colitis model study.
    NLRP3-IN-26
  • HY-162020
    SB1617 98%
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity.
    SB1617
  • HY-162030
    MMT3-72 2996158-39-3 98%
    MMT3-72 is a weak inhibitor of JAK1. MMT3-72 has superior efficacy and reduced p-STAT3 in DSS-induced colitis.
    MMT3-72
  • HY-162063
    hCAIX/XII-IN-9 98%
    hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively.
    hCAIX/XII-IN-9
  • HY-162098
    PROTAC tubulin-Degrader-1 98%
    PROTAC tubulin-Degrader-1 is a α/β/β3-tubulin PROTAC degrader. PROTAC tubulin-Degrader-1 exhibits potent anti-proliferative activity against multiple human tumor cell lines. PROTAC tubulin-Degrader-1 induces G2/M phase arrest and apoptosis and inhibits colony formation in A549 and A549/Taxol cells. PROTAC tubulin-Degrader-1demonstrates potent anti-tumor efficacy in A549 and A549/Taxol (Taxol-resistant) xenograft model. PROTAC tubulin-Degrader-1 can be used for the study of non-small cell lung cancer (NSCLC). (Pink: Tubulin ligand (HY-N2146), Blue: CRBN Ligand (HY-10984), Black: Linker (HY-N6056)).
    PROTAC tubulin-Degrader-1
  • HY-162116
    TLR7 agonist 18 98%
    TLR7 agonist 18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 7.8 μM. TLR7 agonist 18 is not cytotoxic to hTLR7 cotransfected HEK293 cell lines and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. TLR7 agonist 18 can be used in vaccine, asthma, allergy and anti-cancer research.
    TLR7 agonist 18
  • HY-162122
    PPARα/γ agonist 3 3027045-35-5 98%
    PPARα/γ agonist 3 (Compound 4) is a dual agonist of PPARα/γ. PPARα/γ agonist 3 has anti-inflammatory activity, significantly reducing inflammatory markers such as IL-6 and MCP-1 on THP-1 macrophages through NF-κB activation. PPARα/γ agonist 3 can be used in the study of metabolic syndrome and metabolic dysfunction-related fatty liver disease (MAFLD).
    PPARα/γ agonist 3
  • HY-162123
    PPARα/δ agonist 2 3027045-44-6 98%
    PPARα/δ agonist 2 (compound 14) is a potent PPARα and PPARδ agonist with EC50s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects.
    PPARα/δ agonist 2
  • HY-162137
    Hepatoprotective agent-1 1225971-07-2 98%
    Hepatoprotective agent-1 (compound 1b) is a hepatoprotective agenrt. Hepatoprotective agent-1 shows anti-inflammatory, antiapoptotic and antifibrotic effects.
    Hepatoprotective agent-1
  • HY-162139
    Urease-IN-11 517906-12-6 98%
    Urease-IN-11 (Compound 6e) is a competitive urease inhibitor (IC50)=10.41 µM). Urease-IN-11 can be used to study diseases such as urease-related gastritis and peptic ulcer.
    Urease-IN-11
  • HY-162145
    AChE-IN-54 98%
    AChE-IN-54 (compound 3c) is an inhibitor of acetylcholinesterase (AChE) and has anti-lipid oxidation activity.
    AChE-IN-54
  • HY-162147
    Nur77 modulator 3 2097787-75-0 99.01%
    Nur77 modulator 3 is a Nur77 modulator. Nur77 modulator 3 induces Nur77 expression, inhibits hepatic stellate cells (HSCs) activation, and reduces extracellular matrix (ECM) deposition. Nur77 modulator 3 enhances Nur77-denpendent autophagic flux and significantly inhibits the mTORC1 signaling pathway. Nur77 modulator 3 ameliorates HSCs activation, inflammation and hepatic fibrosis in vivo.
    Nur77 modulator 3
  • HY-162166
    COX-2/15-LOX/mPGES1-IN-1 3027770-84-6 98%
    COX-2/15-LOX/mPGES1-IN-1 (Compound 2c) is an inhibitor of COX-2, 15-LOX, and mPGES-1 enzymes with IC50 values of 0.057, 2.39, and 2.8 μM, respectively. COX-2/15-LOX/mPGES1-IN-1 possesses anti-inflammatory activity and can inhibit rat paw edema in vivo experiments.
    COX-2/15-LOX/mPGES1-IN-1
  • HY-162168
    Anti-inflammatory agent 71 3048402-15-6 98%
    Anti-inflammatory agent 71 (Compound 3.2) is an anti-inflammatory agent that can reduce the levels of neutrophils, COX-2, nitrotyrosine, IL-1b, and C-reactive protein, while increasing the level of eNOS.
    Anti-inflammatory agent 71
  • HY-162170
    Anti-inflammatory agent 72 3036299-85-8 98%
    Anti-inflammatory agent 72 (compound 5) is a novel resveratrol derivative hybrid with benzoylhydrazine. Anti-inflammatory agent 72 shows anti-inflammatory and antioxidant activities by activating Nrf2 and inhibiting NF-κB p65/iNOS and MAPKs signaling pathways.
    Anti-inflammatory agent 72
  • HY-162173
    WYZ90 3040313-48-9 98%
    WYZ90 ((compound 6a) is a potent and selective COX-2 inhibitor with IC50 values of 75, 5734, 19940 nM for COX-2, COX-1 and DPPH, respectively. WYZ90 shows antioxidant and analgesic activity.
    WYZ90
  • HY-162228
    VI-60 3050874-42-2 98%
    VI-60 is a dual, orally active inhibitor of cPLA2 and COX-2, which reveals an anti-inflammtory efficacy through the inhibition of p38 MAPK/cPLA2/COX-2/PGE2 pathway.
    VI-60
  • HY-162237
    RIPK1-IN-22 98%
    RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2.
    RIPK1-IN-22
Cat. No. Product Name / Synonyms Application Reactivity